In recent years, several biomarkers, such as procalcitonin (PCT), interleukin-6 (IL-6), soluble triggering receptor expressed on myeloid cells-1, and soluble urokinase-type plasminogen activator receptor, have been investigated to discriminate non-infectious diseases from sepsis. In this issue of Critical Care, Que and colleagues [1] describe the prognostic value of pancreatic stone protein/re generating protein (PSP/reg) concentration in patients with severe infections. PSP/reg functions historically have been reported mainly in regard to the pancreas, and, indeed, pancreatic acinar cells are considered the main source of this protein. PSP/reg was initially described as inhibiting pancreatic stone formation, but later this role was revised [2] . Its serum elevation seemed to be correlated strongly with severe acute pancreatitis and less tightly with chronic pancreatitis and pancreatic cancer [3] . In the '90s, preclinical studies demonstrated that PSP/reg appeared to stimulate islet B-cell growth and regeneration [4] and recently this function was hypothesized to play a role in a therapeutic approach to diabetes mellitus [5] . In recent years, PSP/reg investigations bypassed pancreatic diseases and focused on infection and inflammation [6] . Recent data from Keel and colleagues [7] showed that 83 patients with severe trauma but not pancreatic trauma had PSP/reg upregulation and that the number of patients with post-traumatic septic complications increased significantly. e authors postulated that PSP/ reg binds and activates neutrophils behaving as an acutephase protein that responds to injury during the early phase of infection. Boeck and colleagues [8] demonstrated predictive properties of PSP/reg regarding survival in patients with ventilator-associated pneumonia with two cutoff values for predicting survival and death with high specificity.
concentrations in other types of shock (that is, hemorrhagic or cardiogenic) have been performed. So the high values observed in patients with septic shock may not necessarily be related to the infection pathway but may be due to tissue hypoperfusion or systemic inflam matory response or both. PSP/reg is increased in patients with chronic renal failure, gastric cancer, peptic ulcer, liver cirrhosis, or diabetes mellitus [2] . Que and colleagues [1] reported that 'most patients had at least one comorbid condition' , but unfortunately the authors did not analyze how these comorbidities affected the initial levels of PSP/ reg. A useful biomarker ought to fulfill different clinical needs such as early diagnosis and accurate evaluation of clinical course. A single PSP/reg measurement correlated with the severity of the disease, but we do not know whether this biomarker is reliable in the early diagnosis of bacterial infection or, for instance, in monitoring the therapy response. Que and colleagues added new and interesting findings on the relationships between PSP/reg and patients with severe sepsis. However, there is a long way to go before PSP/reg, along with other biomarkers, can be implemented in clinical practice.
